IL-18/IL-1F4 Antibody (1072F) [Unconjugated]

In the presence of Recombinant Human TNF-alpha (20 ng/mL, Catalog # 210-TA), Recombinant HumanIL-18/IL-1F4 (Catalog # 9124-IL) stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50). Under these conditions, IFN-gamma secretion elicited by Recombinant HumanIL-18/IL-1F4 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Human IL-18/IL-1F4 Monoclonal Antibody (Catalog # MAB9124). The ND50 is typically0.05-0.3 µg/mL.

• Reactivity: Hu
• Applications: B/N
• Clone: 1072F
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

IL-18/IL-1F4 Antibody (1072F) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: E. coli-derived recombinant human IL-18/IL-1F4
  Tyr37-Asp197
  Accession # Q14116
• Specificity: Detects human IL-18/IL-1F4 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: IL18
• Purity Statement: Protein A or G purified from cell culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.05-0.3 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-18/IL-1F4 Antibody (1072F) [Unconjugated]

• Iboctadekin
• IFN-gamma-inducing factor
• IGIF
• IGIFIL-1 gamma
• IL18
• IL-18
• IL-18MGC12320
• IL-1F4
• IL1F4iboctadekin
• IL-1g
• Interferon gamma-inducing factor
• interleukin 18 (interferon-gamma-inducing factor)
• Interleukin-1 gamma
• interleukin-18

Background

Interleukin-18 (IL-18) is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes, gamma δ T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases. IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation (1-3). IL-18 binds to the widely expressed IL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex (4, 5). Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs (6). In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN-gamma production and the cytolytic activity of CD8⁺ T cells and NK cells (7, 8). In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4⁺ T cells and basophils (9, 10). In the presence of IL-1 beta or IL-23, IL-18 induces the antigen-independent production of IL-17 by gamma δ T cells and CD4⁺ T cells (11). IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst (12, 13). In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis (14). Mature human IL-18 shares approximately 63% amino acid sequence identity with mouse and rat IL-18 (15). Alternative splicing in human ovarian cancer generates an isoform that is resistant to Caspase-1 activation (16). A cell surface form can be expressed on M-CSF induced macrophages and released in response to bacterial endotoxin (17).

1. Dinarello, C.A. et al. (2013) Front. Immunol. 4:289.
2. Smith, D.E. (2011) J. Leukoc. Biol. 89:383.
3. Gu, Y. et al. (1997) Science 275:206.
4. Torigoe, K. et al. (1997) J. Biol. Chem. 272:25737.
5. Cheung, H. et al. (2005) J. Immunol. 174:5351.
6. Novick, D. et al. (1999) Immunity 10:127.
7. Fehniger, T.A. et al. (1999) J. Immunol. 162:4511.
8. Yoshimoto, T. et al. (1998) J. Immunol. 161:3400.
9. Yoshimoto, T. et al. (2000) Nat. Immunol. 1:132.
10. Kroeger, K.M. et al. (2009) J. Leukoc. Biol. 86:769.
11. Lalor, S.J. et al. (2011) J. Immunol. 186:5738.
12. Li, J. et al. (2004) Cell. Immunol. 227:103.
13. Elbim, C. et al. (2005) Clin. Diagn. Lab. Immunol. 12:436.
14. Fabbi, M. et al. (2015) J. Leukoc. Biol. 97:665.
15. Ushio, S. et al. (1996) J. Immunol. 156:4274.
16. Gaggero, A. et al. (2004) Oncogene 23:7552.
17. Bellora, F. et al. (2012) Eur. J. Immunol. 42:1618.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IL18
• Uniprot:
  • Q14116()